Gossamer Bio, Inc.
$10.72-$0.51 (-4.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $41.7M
- P/E
- -0.2x
- EV / EBITDA
- -1.3x
- Revenue
- $48.5M
- Net margin
- -351.5%
- ROCE
- -150.0%
Price chart
Technical chartScreen technicals →This period includes a one-day price step on 8 Sep 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +11.9%
- 3M
- Hidden
- 6M
- Hidden
- 1Y
- Hidden
- 5Y
- Hidden
- This period includes a one-day price step on 8 Sep 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
This period includes a one-day price step on 8 Sep 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Day change -$0.51 (-4.5%) from $11.23 to $10.72 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in GOSS, bought on each weekday since 2021.
News & filings
What Gossamer Bio filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Cash on the balance sheet equals 90% of the company's market value.
- The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
- This period includes a one-day price step on 8 Sep 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Read moreShow less
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Shares outstanding
- 233.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $41.7M
- P/E
- -0.2x
- P/B
- -0.3x
- EV / EBITDA
- -1.3x
- EV / Sales
- 4.3x
- P/S
- 0.9x
- 52-week highThis period includes a one-day price step on 8 Sep 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
- 52-week lowThis period includes a one-day price step on 8 Sep 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
- Hidden
Profitability
- Operating margin
- -336.8%
- Net margin
- -351.5%
- EBITDA margin
- -326.9%
- ROE
- 138.8%
- ROCE
- -150.0%
- ROIC
- -297.0%
- ROA
- -98.9%
- Asset turnover
- 0.28
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $48.5M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -57.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 201.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$171.3M
Solvency
- Current ratio
- 2.64
- Debt / Equity
- -1.65
- Debt / Assets
- 1.18
- CFO / Net profit
- 1.01
- Cash / Market cap
- 90.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $48.5M |
| Gross profit | $48.5M |
| Operating expenses | $211.7M |
| Research and development | $174.1M |
| Selling, general and administrative | $37.6M |
| Operating income | -$163.3M |
| Interest and other | -$7.2M |
| Pretax income | -$170.5M |
| Tax and other | -$90.0k |
| Net income | -$170.4M |
Revenue and net profit
Revenue fell 57.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$229.4M |
| FY2023 | $0.00 | -$179.8M |
| FY2024 | $114.7M | -$56.5M |
| FY2025 | $48.5M | -$170.4M |
Cash flows
FY2025: -$171.3M from operations, -$171.3M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$187.0M | -$187.5M |
| FY2023 | -$159.2M | -$159.2M |
| FY2024 | -$3.5M | -$3.5M |
| FY2025 | -$171.3M | -$171.3M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $48.5M-57.7%1Y
- EBITDA
- -$158.5M
- Net profit
- -$170.4M
- Cash from operations
- -$171.3M
- Free cash flow
- -$171.3M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $48.5M | -$158.5M | -$170.4M | -$171.3M | 138.8% | -57.7% | +201.4% |
Monthly returns
Month-by-month returns of GOSS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $172.3M |
| Current assets | $167.6M |
| Non-current assets | $4.6M |
| Liabilities | $295.0M |
| Current liabilities | $63.4M |
| Non-current liabilities | $231.6M |
| Equity | -$122.8M |
| Paid-in capital | $1.3B |
| Retained earnings | -$1.4B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; GOSS highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Actuate Therapeutics, Inc. Common stock, Tevogen Bio Holdings Inc., Tvardi Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Gossamer Bio, Inc.GOSSthis company | $41.7M | -0.2x | -0.3x | 138.8% | -1.3x |
| DocGo Inc.DCGO | $56.3M | -0.3x | 0.4x | -126.7% | -0.5x |
| aTyr Pharma, Inc.ATYR | $50.3M | -0.7x | 0.7x | -109.8% | -0.7x |
| Myomo, Inc.MYO | $49.8M | -3.2x | 4.4x | -136.6% | -4.4x |
| Actuate Therapeutics, Inc. Common stockACTU | $46.4M | -2.1x | 5.9x | -280.5% | — |
| Accuray IncorporatedARAY | $43.5M | -27.3x | 0.5x | -2.0% | 8.0x |
| Tevogen Bio Holdings Inc.TVGN | $41.3M | -1.6x | -2.4x | 154.2% | -1.9x |
| INmune Bio Inc.INMB | $35.9M | -0.8x | 1.5x | -195.3% | -0.4x |
| Tvardi Therapeutics, Inc.TVRD | $28.9M | -1.6x | 1.4x | -87.0% | -0.3x |
| Peer median | — | -1.6x | 1.1x | -118.2% | -0.5x |
Year-to-date ROI
GOSS since 1 January, against earlier years.
Historical volatility
GOSS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2024 | -52.2% |
| FY2025 | -336.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $48.5M |
| Operating expensesOperating Expense | $211.7M |
| Research and developmentResearch And Development | $174.1M |
| Selling, general and administrativeSelling General And Administration | $37.6M |
| Total expensesTotal Expenses | $211.7M |
| Operating incomeOperating Income | -$163.3M |
| Interest and other | |
| Pretax incomePretax Income | -$170.5M |
| TaxTax Provision | -$90.0k |
| Net incomeNet Income | -$170.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $172.3M |
| Current assetsCurrent Assets | $167.6M |
| Non-current assetsTotal Non Current Assets | $4.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $295.0M |
| Current liabilitiesCurrent Liabilities | $63.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $231.6M |
| EquityTotal Equity Gross Minority Interest | -$122.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$171.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$171.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$170.4M |
| Depreciation and amortisationDepreciation And Amortization | $1.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $1.0M |
| Depreciation | $1.0M |
| Amortization of securitiesAmortization Of Securities | -$7.3M |
| Stock-based compensationStock Based Compensation | $10.6M |
| Operating gains and lossesOperating Gains Losses | $0.00 |
| Gain loss on investment securitiesGain Loss On Investment Securities | $0.00 |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Change in working capitalChange In Working Capital | -$13.6M |
| Other non-cash itemsOther Non Cash Items | $8.5M |
| Investing cash flowInvesting Cash Flow | $156.4M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $156.4M |
| Capital expenditureCapital Expenditure | -$80.0k |
| Purchase of PP&EPurchase Of PPE | -$80.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$80.0k |
| Purchase of investmentsPurchase Of Investment | -$227.1M |
| Sale of investmentsSale Of Investment | $383.5M |
| Net investment purchases and salesNet Investment Purchase And Sale | $156.4M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | $6.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $6.4M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | $0.00 |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | $0.00 |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $6.4M |
| Change in cashChanges In Cash | -$8.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 14.0% |
| Cash at the start of the yearBeginning Cash Position | $46.1M |
| Cash at the end of the yearEnd Cash Position | $37.7M |
| Free cash flowFree Cash Flow | -$171.3M |
| Supplemental |
Learn while you research
Academy chapters picked for Gossamer Bio, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read